Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis

Ophthalmology

Volumn 121, Issue 8, 2014, Pages

  Sun, Catherine Q ^a   Lalitha, Prajna ^b   Prajna, N Venkatesh ^b   Karpagam, Rajarathinam ^b   Geetha, Manoharan ^b   O'Brien, Kieran S ^a   Oldenburg, Catherine E ^a   Ray, Kathryn J ^a   McLeod, Stephen D ^a,c   Acharya, Nisha R ^a,c   Lietman, Thomas M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ARAVIND EYE CARE SYSTEM   (India)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abbreviations and Acronyms; CI; confidence interval; ECV; epidemiologic cutoff value; logarithm of the minimum angle of resolution; logMAR; median minimum inhibitory concentration; MIC; minimum inhibitory concentration; MUTT I; Mycotic Ulcer Treatment Trial I; ninetieth percentile minimum inhibitory concentration; therapeutic penetrating keratoplasty; TPK

Indexed keywords

NATAMYCIN; VORICONAZOLE; ANTIFUNGAL AGENT; EYE DROPS;

ALTERNARIA; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; BIPOLARIS; CONTROLLED STUDY; CORNEA PERFORATION; CURVULARIA; FEMALE; FUSARIUM; HUMAN; KERATOMYCOSIS; LASIODIPLODIA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PENETRATING KERATOPLASTY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPECTACLES; TREATMENT OUTCOME; VISUAL ACUITY; CLINICAL TRIAL; COMPARATIVE STUDY; CORNEA EPITHELIUM; CORNEAL PERFORATION; CORNEAL ULCER; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EPITHELIZATION; EYE INFECTIONS, FUNGAL; FUNGUS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; PATHOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SCAR; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; CICATRIX; CORNEAL PERFORATION; CORNEAL ULCER; DOUBLE-BLIND METHOD; EPITHELIUM, CORNEAL; EYE INFECTIONS, FUNGAL; FUNGI; HUMANS; KERATOPLASTY, PENETRATING; MICROBIAL SENSITIVITY TESTS; NATAMYCIN; OPHTHALMIC SOLUTIONS; RE-EPITHELIALIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VORICONAZOLE;

EID: 84905508560     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.03.004     Document Type: Article

References (25)

1. J.P. Whitcher, and M. Srinivasan Corneal ulceration in the developing world - a silent epidemic Br J Ophthalmol 81 1997 622 623
2. M.A. Tanure, E.J. Cohen, and S. Sudesh et al. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania Cornea 19 2000 307 312
3. R.H. Rosa Jr., D. Miller, and E.C. Alfonso The changing spectrum of fungal keratitis in south Florida Ophthalmology 101 1994 1005 1013
4. D.C. Ritterband, J.A. Seedor, and M.K. Shah et al. Fungal keratitis at the New York Eye and Ear Infirmary Cornea 25 2006 264 267
5. U. Gopinathan, P. Garg, and M. Fernandes et al. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India Cornea 21 2002 555 559
6. M.J. Bharathi, R. Ramakrishnan, and S. Vasu et al. Epidemiological characteristics and laboratory diagnosis of fungal keratitis. A three-year study Indian J Ophthalmol 51 2003 315 321
7. M. Srinivasan Fungal keratitis Curr Opin Ophthalmol 15 2004 321 327
8. J.H. Rex, and M.A. Pfaller Has antifungal susceptibility testing come of age? Clin Infect Dis 35 2002 982 989
9. M.P. Weinstein, J.R. Murphy, L.B. Reller, and K.A. Lichtenstein The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis Rev Infect Dis 5 1983 54 70
10. B.L. Shapiro, P. Lalitha, and A.R. Loh et al. Susceptibility testing and clinical outcome in fungal keratitis [letter] Br J Ophthalmol 94 2010 384 385
11. P. Lalitha, N.V. Prajna, and C.E. Oldenburg et al. Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial Cornea 31 2012 662 667
12. C. Lass-Florl, G. Kofler, and G. Kropshofer et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis J Antimicrob Chemother 42 1998 497 502
13. J.L. Rodriguez-Tudela, L. Alcazar-Fuoli, and I. Cuesta et al. Clinical relevance of resistance to antifungals Int J Antimicrob Agents 32 suppl 2008 S111 S113
14. F. Marangon, D. Miller, J. Giaconi, and E. Alfonso In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens Am J Ophthalmol 137 2004 820 825
15. P. Lalitha, B.L. Shapiro, and M. Srinivasan et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis Arch Ophthalmol 125 2007 789 793
16. N.V. Prajna, T. Krishnan, and J. Mascarenhas et al. Mycotic Ulcer Treatment Trial Group. The Mycotic Ulcer Treatment Trial: a randomized trial comparing natamycin vs voriconazole JAMA Ophthalmol 131 2013 422 429
17. J.H. Rex, B.D. Alexander, and D. Andes et al. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard 2nd ed. 2008 Clinical and Laboratory Standards Institute Wayne, PA CLSI document M38-A2: vol 28, no 16
18. A. Espinel-Ingroff, D.J. Diekema, and A. Fothergill et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document) J Clin Microbiol 48 2010 3251 3257
19. J.H. Rex, M.A. Pfaller, and J.N. Galgiani et al. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections Clin Infect Dis 24 1997 235 247
20. J.H. Rex, M.A. Pfaller, and T.J. Walsh et al. Antifungal susceptibility testing: practical aspects and current challenges Clin Microbiol Rev 14 2001 643 658
21. D.M. O'Day Selection of appropriate antifungal therapy Cornea 6 1987 238 245
22. M.A. Thiel, A.S. Zinkernagel, and J. Burhenne et al. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis Antimicrob Agents Chemother 51 2007 239 244
23. D. Lau, M. Fedinands, and L. Leung et al. Penetration of voriconazole, 1%, eyedrops into human aqueous humor: a prospective open-label study Arch Ophthalmol 126 2008 343 346
24. G.A. Vemulakonda, S.M. Hariprasad, and W.F. Mieler et al. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans Arch Ophthalmol 126 2008 18 22
25. P. Lalitha, C.Q. Sun, and N.V. Prajna et al. In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial Am J Ophthalmol 157 2014 318 326